22-24 January, 2018
London, UK

Media Center


Maximising ROI Within Clinical Trial Supply

With the help of industry experts, this Pharma IQ infographic highlights key methods to maximise returns within clinical trial supply.

Download the infographic below. 

Innovation in Clinical Trial Supply

Innovation is thought to be a keystone in the process of being competitive in any market. Within clinical trial supply, a lack of innovation can be costly in regards to a range of variables.

With this in mind, Pharma IQ discusses the latest trailblazing techniques in the arena with a panel of Clinical Trial Supply specialists.

Planning & Forecasting Considerations in Global Clinical Trial Supply

Often orchestrated on a global scale, clinical trials require the production and distribution of the investigational pharmaceuticals to thousands of participants over several years. 

Here, Clinical Trial Supply Europe presents the results of its 2016 Report focused on the realms of planning and forecasting supply within global clinical trials. 

Case Study: An Inside Look Into Site Centricity

Pharma IQ speaks to Dr Samantha Carmichael, Lead Pharmacist Clinical Trials of NHS Greater  Glasgow & Clyde and Mandy Wan, Lead Paediatric Research Pharmacist, Evelina London Children’s Hospital in regards to the growing general culture of site centricity in today’s clinical trials.

Hurdling the Stumbling Blocks in Clinical Trial Supply

The supply of clinical trials is the one of the most onerous tasks in this pivotal late phase of drug development. The task is further complicated by the ongoing complexity and sheer expanse of the global clinical trial supply chain. Unsurprisingly, efficiency is paramount to ensure there are no delays imposed on the drug reaching the market and, needless to say, clinical trial supply managers do not want to be the individuals responsible for jeopardising or blocking a pharmaceutical’s market access. With this in mind, Pharma IQ examines the clinical trial supply pain points and the responding technologies and tactics which have the potential to optimise current clinical trial supply practices.

Top Featured

Clinical Trial Supply Infographic: Facing Clinical Trial Supply Challenges

45.5% of clinical trial supply professionals consider Brazil to be the most challenging market to work in
Did you know that more than 52% of clinical trials professionals express a high interest in labelling standardisation? We did. The Clinical Trial Supply Europe Conference is now five years old and we at Pharma IQ wanted to hear from the community what their challenges and priorities in this area are. We ran the Clinical Trial Supply Outlook 2015 Survey through July and August. Our community of Clinical Trials professionals let us know the latest from this changing field.


Minimising Wastage in Time and Money

The operation of clinical trials are integral to the progression of the pharmaceutical industry. These trials can be orchestrated on a global scale, producing and distributing the drug in question to participants over several years.

Therefore, the supply of these trials represents one of the biggest challenges to be navigated. Undoubtedly, the efficient management of clinical trial supply entails regulating two dominant variables: Time and money. 


Sample Delegate List - CTS

To see a sample list of who will be attending Clinical Trial Supply Europe in January, please download the sample delegate list.


Forecasting a Brighter Future for Clinical Trial Supply in Emerging Markets- An Interview with Adrian Peskett

Pharma IQ interviewed Adrian Peskett, Clinical Supply Logistics Director at Pfizer Ltd. about his predictions for the future of clinical trial supply in emerging markets. Adrian also speaks about the importance of forecasting in emerging markets and the difficulties in standardising strategy, while meeting countries' individual needs.


The Growing Diversity Between SME Biotech Business Models

As with most sectors, the biotechnology industry is driven by the innovative vigor of small or medium-sized enterprises (SMEs). Most biotechnology SMEs grow slowly and depend on limited financial opportunities from external sources. However, the lack of resources in larger companies and fundamental problems in the models of business prevent most SMEs from succeeding. Competition from larger companies and the lack of marketing capabilities have also battered many opportunities for SMEs. There are three major factors that contribute to the restriction of growth of biotech SMEs: Complicated patenting and costly regulatory systems. Insufficient risk capital for early-stage development. The incongruous marriage between science and business. It is crucial for all new and existing biotech companies to take these three factors into their business model. The key implications of SME research and development depend on the dynamic business models, i.e. a fluid construct model instead of concrete

The Clinical Trials Process

What are the 7 Deadly Sins of Quality Assurance and Quality Control? Download our free QA QC eBook now to find out!   Clinical trials play an extremely important role in helping pharmaceutical companies get their products to market. They are designed to ensure the safety and efficacy of new products before they are marketed to the public and they are needed for companies to be granted a licence for their drugs. Approval has to be sought by the regulatory authorities in the individual countries where the pharmaceutical clinical trials are being conducted before they can begin. In the United States, this is the Food and Drugs Administration, while in the UK, the Clinical Trials unit of the Medicines and Healthcare Products Regulatory Authority is tasked with the responsibility. Pharmaceutical clinical trials can be carried out either in-house or by clinical research organisations (CRO), which are also sometimes known as contract research organisations. The Association of

Site Perspectives on Clinical Trial Supply- Samantha Carmichael

Samantha Carmichael Lead Pharmacist Clinical Trials NHS Greater Glasgow & Clyde Samantha Carmichael has 18 years experience as a pharmacist, having spent time in many different areas of pharmacy, including hospital pharmacy and within the private sector working for a large international pharmaceutical company.  She is currently the Lead Pharmacist for Clinical Trials and one of the Lead Sponsor Representatives within NHS Greater Glasgow & Clyde Healthboard. NHS GGC is the largest healthboard in the UK, providing healthcare services to a population of 1.2 million in the West of Scotland.  She manages a team of pharmacists and pharmacy technicians who deliver on studies sponsored by NHS GGC or co-sponsored with the University of Glasgow, as well as hosting around 400 CTIMPs across 4 research portfolios, covering all phases and therapeutic areas.  She has practised as a clinical pharmacist in the areas of oncology, critical care and anaesthetics. 

Requirements for Local Language Labeling in Clinical Trials

Global clinical trials labeling can be a complex subject and is an integral part of clinical trials supplies management. The landscape is varied in terms of the systems and processes employed in designing, populating and printing labels - including booklets and instructions for use (IFUs). To help you clear up any confusion surrounding local language labeling, Prisym have put together this whitepaper. Find out about the critical elements involved in printing labels, booklets and IFUs and how to effectively use a software solution to manage the whole process.

Building the perfect Clinical Trial Supply Team

To help you build an effective team, Pharma Logistics IQ examines the various traits needed in an optimal clinical trial supply team.